ELTX Stock Forecast & Price Target

Elicio Therapeutics is supported by a differentiated AMP-based platform that has repeatedly shown strong lymph-node targeting, high immunogenicity, and broad applicability across KRAS-driven cancers, which strengthens confidence in its scientific and commercial potential. The lead asset, ELI-002 7P, has produced a 99% mKRAS-specific T cell response rate in 90 evaluable Phase 2 patients, with 85% generating both CD4 and CD8 responses and 87.6% showing antigen spreading, while the company ended 2Q26 with about $37.5M in pro forma cash and a reported net loss of $0.43 per share. Although AMPLIFY-7P missed its primary DFS endpoint, the R0-resected subgroup showed a median DFS of 23.8 months versus 12.8 months, supporting a more focused Phase 3 design and preserving the investment case.

Elicio Therapeutics is challenged by a fragile fundamental profile because its lead asset, ELI-002 7P, remains dependent on Phase 2 readout uncertainty, an MRD-agnostic population, and possible FDA requests for additional trials even if the DFS endpoint is met. Its intellectual property is also not fully de-risked, as the 2025 10-K says the portfolio largely comprises pending applications, MIT controls prosecution and maintenance of key licensed patents, and co-owned rights with Cornell create a material commercialization risk for ELI-007. Financially, the company has a limited cash runway through 4Q26 and may need additional equity financing, with concentrated ownership and a ~$6M March 2024 private placement underscoring dependence on external support and dilution risk.